You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of An Integrated High Throughput Imaging and Image Analysis Platform for Muscle

    SBC: CytoInformatics LLC            Topic: NIA

    DESCRIPTION provided by applicant There is growing awareness that weakness of muscle is a significant biomedical health issue associated with many different chronic diseases and aging There are a variety of different diseases that affect muscle including muscular dystrophy fibromyalgia cerebral palsy amyotrophic lateral sclerosis and myasthenia gravis each of which carries its own uniqu ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Development of a non-fibrillic amyloid-beta oligomer selective positron emission tomography imaging diagnostic for Alzheimer.

    SBC: Acumen Pharmaceuticals, Inc            Topic: NIA

    In the United States in an estimated million people suffered from Alzheimer s disease AD with as many as being undiagnosed Alzheimer s Association Three stages of AD are proposed National Institute on Aging and the Alzheimer s Association preclinical AD mild cognitive impairment MCI due to AD and dementia due to AD The preclinical stage is proposed to begin ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a Scalable, Cloud-Based Microbiome Big Data Analytics System

    SBC: WHOLE BIOME INC.            Topic: 400

    The human microbiome has emerged as a hitherto unknown causal factor in a number of disease ranging from cancer cardiovascular disease and obesity To understand the biochemical mechanisms of the human microbiome in these diseases researchers must be able to store biochemical pathway transcriptomic and metabolomic datasets in a coherent and compatible form We propose to construct a cloud ba ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Development of Optimized AAV Serotype Vectors for Human Gene Therapy

    SBC: Medosome Biotec, LLC            Topic: NIAID

    DESCRIPTION provided by applicant Adeno associated virus AAV is a non pathogenic human parvovirus and recombinant AAV vectors have gained significant attention owing to their safety and in some cases clinical efficacy in a number of Phase I II clinical trials However relatively large vector doses are needed to achieve clinical efficacy and such high doses can lead to host immune respon ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Development of PAR Pepducins for the Treatment of Atopic Dermatitis

    SBC: OASIS PHARMACEUTICALS, LLC            Topic: NIAMS

    DESCRIPTION provided by applicant Atopic dermatitis AD or severe eczema is a very common life long skin disease with of adults in the US requiring systemic therapy Clinical manifestations of AD include multiple inflamed lesions erosions accompanied by lichenification thick leathery skin fibrotic papules and severely dry skin with increased susceptibility to infection A major uncont ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Development of peptide inhibitors for neuroinflammation and neurodegeneration

    SBC: PROVAIDYA            Topic: NIA

    DESCRIPTION provided by applicant The prevalence of Alzheimerandapos s disease AD is poised to increase exponentially with the growing aging population worldwide In the United States total annual costs of AD care are projected to increase from $ billion in to over $ trillion in Paucity of disease modifying therapies capable of slowing the disease progression is an acute unmet ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. High speed Intraoperative Assessment of Breast Tumor Margin using MarginPAT

    SBC: Vibronix, Inc.            Topic: O

    After a breast conserving therapy histology is often performed to check whether the excised tumor specimen is surrounded by a sufficient amount of normal tissue If a positive margin is identified then a second operation will be performed Currently the re operation rate is which raises a need for intraoperative detection of residual cancers The current intraoperative tools for margin ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. improving Cas9 mediated homologous recombination in pluripotent stem cells

    SBC: APPLIED STEMCELL, INC.            Topic: 200

    DESCRIPTION provided by applicant Gene correction therapy is one of the most important application directions in regenerative medicine Scientists are exploring various approaches to introduce targeted mutations corrections to pluripotent stem cells PSCs to establish disease models and or to develop therapeutic agents Emerging technologies such as Zinc Finger Nucleases ZFNs Transcription ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Infectious Disease Diagnostics and Differentiation of Viral vs. Bacterial Infections for Point of Care Applications

    SBC: GENECAPTURE, INC.            Topic: CBD15C001

    The modern warfighter faces the constant threat of endemic infections, multi-drug resistant bacteria and Biological Warfare Agents. In order to provide accurate front-line treatment that will curtail the overuse of antibiotics, a rapid and robust molecula

    STTR Phase I 2016 Department of DefenseOffice for Chemical and Biological Defense
  10. Inhibitors of the viral nucleoprotein polymerase co factor interaction for human RSV and MPV therapy

    SBC: MICROBIOTIX, INC.            Topic: NIAID

    Human respiratory syncytial virus hRSV and human metapneumovirus hMPV are non segmented negative strand viruses NNSV and are the leading causes of acute respiratory tract infections in infants worldwide In addition hRSV is a significant cause of disease in elderly populations and can often be fatal for patients with compromised immune systems Currently no vaccines are available and exis ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government